Abstract
Objective: Phenylketonuria (PKU) is a rare inherited metabolic disorder characterised by elevated phenylalanine (Phe) concentrations that can exert neurotoxic effects if untreated or upon treatment discontinuation. This systematic review supported by expert opinion aims to raise awareness among the neurological community on neurological complications experienced by adults with PKU (AwPKU). Methods: The PubMed database was searched for articles on neurological signs and symptoms in AwPKU published before March 2022. In addition, two virtual advisory boards were held with a panel of seven neurologists and two metabolic physicians from Germany and Austria. Findings are supported by three illustrative patient cases. Results: Thirty-nine articles were included. Despite early diagnosis and treatment, neurological signs and symptoms (e.g. ataxia, brisk tendon reflexes, tremor, visual impairment) can emerge in adulthood, especially if treatment has been discontinued after childhood. In PKU, late-onset neurological deficits often co-occur with cognitive impairment and psychiatric symptoms, all of which can be completely or partially reversed through resumption of treatment. Conclusion: Ideally, neurologists should be part of the PKU multidisciplinary team, either to bring lost to follow-up patients back to clinic or to manage symptoms in referred patients, considering that symptoms are often reversible upon regaining metabolic control. The current findings have been combined in a leaflet that will be disseminated among neurologists in Germany and Austria to create awareness.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Journal of Neurology |
| Jahrgang | 270 |
| Ausgabenummer | 8 |
| Seiten (von - bis) | 3675-3687 |
| Seitenumfang | 13 |
| ISSN | 0340-5354 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 08.2023 |
Fördermittel
This work was supported by BioMarin Deutschland GmbH and BioMarin Pharmaceutical Inc. Dr. Tina Mainka was in addition supported by the BIH-Charité Clinician Scientist Program of the Charité-Universitätsmedizin Berlin and the Berlin Institute of Health.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 10 – Weniger Ungleichheiten
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)
DFG-Fachsystematik
- 2.23-07 Klinische Neurologie, Neurochirurgie und Neuroradiologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Characterisation and differential diagnosis of neurological complications in adults with phenylketonuria: literature review and expert opinion“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver